Evidence map›Paper›PMID 34820524›Full record

ArticleClinical mass spectrometry (Del Mar, Calif.)2020

Analysis of 17 fentanyls in plasma and blood by UPLC-MS/MS with interpretation of findings in surgical and postmortem casework.

Jonathan P Danaceau, Michelle Wood, Melissa Ehlers, Thomas G Rosano

Open access · greenAbstract read
In one paragraph

Article in Clinical mass spectrometry (Del Mar, Calif.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Definitive urine drug testing in emergency medicine: Recreational and psychiatric drug findings.Journal of mass spectrometry and advances in the clinical lab · 2025
    Article
  3. Blood concentrations of new synthetic opioids.International journal of legal medicine · 2022
    Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Jonathan P DanaceauWaters Corporation, Milford, MA, USA.
Michelle WoodWaters Corporation, Wilmslow, UK.
Melissa EhlersAlbany Medical Center (AMC), Albany, NY, USA.
Thomas G RosanoAlbany Medical Center (AMC), Albany, NY, USA.
Albany Medical Center Hospital · USWaters (United Kingdom) · GBWaters (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The opioid crisis is linked to an increased misuse of fentanyl as well as fentanyl analogs that originate from the illicit drug market. Much of our current understanding of fentanyl and fentanyl analog use in our communities comes from postmortem toxicology findings. In the clinical settings of addiction medicine and pain management, where the opioid abuse potential is high, the use of fentanyl, as well as specific fentanyl analogs, may be underestimated due to limited plasma testing and limited availability of assays with suitable analytical sensitivity and selectivity to detect misuse of fentanyls. We report plasma and blood assays for 17 fentanyls (these include fentanyl, fentanyl analogs, fentanyl metabolites and synthetic precursors) in clinical, and medical examiner, casework. A mixed-mode solid phase extraction of diluted plasma or precipitated blood was optimized for maximum recovery of the fentanyls with minimized matrix effects. Analysis was performed using a Waters ACQUITY UPLC I-Class interfaced with a Waters Xevo TQ-S micro tandem quadrupole mass spectrometer. Method parameters were optimized and validated for precision, accuracy, carryover, linearity and matrix effects. Application studies were performed in postmortem blood obtained in 44 fentanyl-related fatalities and in serial plasma samples from 18 surgical patients receiving intravenous fentanyl therapy while undergoing parathyroidectomy. Fentanyls found in postmortem cases included fentanyl, norfentanyl, despropionyl-fentanyl (4-ANPP), beta-hydroxy fentanyl (β-OH fentanyl), acetyl fentanyl, acetyl norfentanyl, methoxyacetyl fentanyl, furanyl fentanyl, cyclopropyl fentanyl, and para-fluorobutyryl fentanyl, with fentanyl, norfentanyl, 4-ANPP and β-OH fentanyl predominating in frequency. Fentanyl concentrations ranged from 0.2 to 56 ng/mL and fentanyl was nearly always found with 4-ANPP, norfentanyl and β-OH fentanyl. Concentrations of other fentalogs ranged from <1 to 84 ng/mL (extrapolated). In the surgical cases, fentanyl was detected and quantified along with norfentanyl and β-OH fentanyl, but without detection of 4-ANPP in any of the samples. The association and relative concentrations of β-OH fentanyl, fentanyl and norfentanyl in the postmortem and clinical studies indicated a metabolic, rather than an illicit, source of β-OH fentanyl.

Indexed as

4-ANPP, 4-Anilino-N-phenethylpiperidine (despropionyl-fentanyl)ACN, AcetonitrileClinical and postmortem casework applicationsFentanylFentanyl analogsFentanyl metabolitesFentanyl precursorsLC-MS, liquid chromatography-mass spectrometryLLOQ, lower limit of quantitationMRM, multiple reaction monitoringPFBF, para-fluorobutyryl fentanylQuantitative UPLC-MS/MS analysisUPLC-MS/MS, ultra-performance liquid chromatography-tandem mass spectrometryβ-OH fentanyl, beta-hydroxy fentanyl

Identifiers

PMID34820524
PMCPMC8601016
OpenAlexW3097965568

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.